Non Small Cell Lung Cancer Clinical Trials in Grand Rapids, Michigan

21 studies are recruiting for non small cell lung cancer in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

   The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Grand Rapids, Michigan

   Locations

   328 in total

   Run by

   AstraZeneca

   See if you can join NCT06692738 on ClinicalTrials.gov

3. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

   This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   BAMF Health, Grand Rapids, Michigan

   Locations

   14 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07020117 on ClinicalTrials.gov

4. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

5. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

6. Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cancer & Hematology Centers of Western Michigan - East /ID# 261826, Grand Rapids, Michigan

   Locations

   61 in total

   Run by

   AbbVie

   See if you can join NCT06236438 on ClinicalTrials.gov

7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids, Michigan

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

8. A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

   This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   15 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT07361562 on ClinicalTrials.gov

9. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Cancer & Hematology Centers, Grand Rapids, Michigan

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

10. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

    Locations

    52 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06586515 on ClinicalTrials.gov

11. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Cancer and Hematology Centers of Western Michigan ( Site 4003), Grand Rapids, Michigan

    Locations

    229 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

12. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Grand Rapids, Michigan

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov

13. Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Grand Rapids, Michigan

    Locations

    287 in total

    Run by

    AstraZeneca

    See if you can join NCT06357533 on ClinicalTrials.gov

14. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    12 in total

    Run by

    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

15. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    66 in total

    Run by

    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

16. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

17. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

    Stage

    Phase 1

    Ages

    18 to 100

    Site

    BAMF Health, Grand Rapids, Michigan

    Locations

    29 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06562192 on ClinicalTrials.gov

18. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Corewell Health - Butterworth Hospital, Grand Rapids, Michigan

    Locations

    372 in total

    Run by

    Pfizer

    See if you can join NCT06758401 on ClinicalTrials.gov

19. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest /ID# 248685, Grand Rapids, Michigan

    Locations

    48 in total

    Run by

    AbbVie

    See if you can join NCT05005403 on ClinicalTrials.gov

20. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    20 in total

    Run by

    Astellas Pharma Inc

    See if you can join NCT07094204 on ClinicalTrials.gov

21. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    13 in total

    Run by

    Tasca Therapeutics

    See if you can join NCT07030257 on ClinicalTrials.gov